Literature DB >> 15112070

Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection.

S Takakura1, N Fujihara, T Saito, T Kudo, Y Iinuma, S Ichiyama.   

Abstract

In a 1-year national surveillance program of Candida bloodstream infections in Japan, clinical factors predicting fluconazole resistance and survival of the patients were analyzed. Blood isolates and complete clinical histories were obtained from 326 patients. Fluconazole-resistant isolates were found in 15 (4.6%) of the cases. Univariate analysis of the demographic and clinical factors associated with fluconazole resistance revealed that age, hematologic malignancy, neutropenia, and immunosuppression were of statistical significance. A multiple logistic regression model showed that only hematologic malignancy as the underlying disease (odds ratio, 6.6; 95% confidence interval, 1.6-26.9; P=0.009) was independently associated with resistance. In 242 cases in which data regarding management and prognosis were available, the 30-day survival rate was 68.4%. In the univariate analysis of factors predicting survival, a significant association was found for Candida species, age of the patient, neutropenia, recent abdominal surgery, removal of the central venous catheter, and use of appropriate antifungal therapy. In the multivariate analysis, removal of the central venous catheter (odds ratio, 6.0; 95% confidence interval, 2.2-16.1; P<0.001) and the use of appropriate therapy (odds ratio, 2.1; 95% confidence interval, 1.1-4.1; P=0.03) were independent factors significantly associated with survival after the diagnosis of Candida bloodstream infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15112070     DOI: 10.1007/s10096-004-1128-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  48 in total

1.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

2.  Risk factors for candidemia in patients with acute lymphocytic leukemia.

Authors:  H M Richet; A Andremont; C Tancrede; J L Pico; W R Jarvis
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

3.  Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals.

Authors:  A Voss; J A Kluytmans; J G Koeleman; L Spanjaard; C M Vandenbroucke-Grauls; H A Verbrugh; M C Vos; A Y Weersink; J A Hoogkamp-Korstanje; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

Review 4.  International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.

Authors:  J E Edwards; G P Bodey; R A Bowden; T Büchner; B E de Pauw; S G Filler; M A Ghannoum; M Glauser; R Herbrecht; C A Kauffman; S Kohno; P Martino; F Meunier; T Mori; M A Pfaller; J H Rex; T R Rogers; R H Rubin; J Solomkin; C Viscoli; T J Walsh; M White
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

5.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Authors:  M A Pfaller; D J Diekema; R N Jones; S A Messer; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

7.  Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999.

Authors:  Manuel Cuenca-Estrella; Laura Rodero; Guillermo García-Effrón; Juan L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

9.  Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland.

Authors:  Lena Rós Asmundsdóttir; Helga Erlendsdóttir; Magnús Gottfredsson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia.

Authors:  R S Schwartz; F R Mackintosh; S L Schrier; P L Greenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

View more
  18 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

Review 2.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Authors:  Isabel Cuesta; Concha Bielza; Manuel Cuenca-Estrella; Pedro Larrañaga; Juan L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

4.  Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; Daniel Diekema; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

5.  Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Authors:  Alexander J Lepak; Karen Marchillo; Jaimie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 6.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

7.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 8.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

9.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  John W Baddley; Mukesh Patel; Sujata M Bhavnani; Stephen A Moser; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

10.  Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.

Authors:  Juan L Rodríguez-Tudela; Benito Almirante; Dolors Rodríguez-Pardo; Fernando Laguna; J Peter Donnelly; Johan W Mouton; Albert Pahissa; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.